St. Jude Medical Inc.
) posted a 6.25% rise in adjusted net earnings per share to $1.02
for the second quarter of 2014 from 96 cents in the year-ago
quarter. With this, the St. Paul, MN-based medical device maker's
earnings per share beat the Zacks Consensus Estimate by a couple of
cents and outdid the company's own guidance of 99 cents to $1.01
for the quarter.
Net adjusted earnings rose 7.3% to $295 million from $275 million
in the 2013-second quarter. Reported earnings were $270 million or
93 cents per share in the quarter, compared with $115 million or 40
cents per share in the comparable quarter of 2013.
Revenues grew about 3.2% (both in reported and constant-currency)
to $1,448 million for the quarter, which surpassed the Zacks
Consensus Estimate of $1,436 million but lied within the company's
own guided range of $1,380 to $1,460 million. Favorable foreign
currency translation boosted revenues by roughly $4 million in the
Revenues from the international market rose 6.1% to $779 million,
accounting for 53.8% of total revenues. However, revenues from the
U.S. were flat at $669 million compared with the year ago level,
accounting for 46.2% of total revenues.
Product Division Results
Cardiac Rhythm Management (CRM)
division, revenues went up roughly 2.0% (both in reported and
constant-currency) to $733 million. U.S. revenues upped 0.5% to
$382 million while international revenues zoomed 3.8% to $351
million in the quarter.
In the CRM division, implantable cardiac defibrillator (ICD)
revenues escalated 1.8% (1% in constant-currency) to $462 million.
Meanwhile, pacemaker revenues scaled up 2.65% to $271 million
compared with the prior year quarter. At constant-currency,
pacemaker revenues rose by 3% in the quarter.
Atrial Fibrillation (AF)
division, revenues scaled up 8.4% to $257 million, while at
constant currency it increased 8% over the second quarter of 2013.
International revenues grew 9.7% to $159 million while U.S.
revenues rose 6.5% to $98 million in the quarter.
division, revenues went up 3.2% to $351 million in the quarter and
roughly 3% at constant-currency. Revenues from the international
market rose 4.5% to $233 million and from the U.S. market inched up
0.9% to $118 million.
In the cardiovascular division, vascular product revenues edged up
roughly 1.0% to $180 million. Meanwhile, structural heart product
revenues increased 6.0% to $171 million for the quarter.
division, revenues went down nearly 1.0% to $107 million in the
second quarter, both on reported and constant-currency bases.
Revenues from the U.S. ebbed 11.0% to $71 million but revenues from
the international market improved 29% to $36 million in the
St. Jude Medical had cash and cash equivalents of $1,580 million as
of Jun 28, 2014, up 15.1% from $1,373 million as of Dec 28, 2013.
Total debt rose 17.5% to $4,206 million as of Jun 28, 2014 compared
with $3,580 million as of Dec 28, 2013. Consequently,
debt-to-capitalization increased 620 basis points to 51.0% from
44.8% as of Dec 28, 2013.
For the third quarter of 2014, St. Jude Medical expects revenues in
the range of $1,315 to $1,395 million while the company anticipates
adjusted net earnings per share to lie between 95 and 97 cents for
the quarter. The current Zacks Consensus Estimates for earnings per
share and revenues for the quarter are pegged at 96 cents and
For full year 2014, St. Jude Medical upgraded its revenues guidance
to the range of $5,640 to $5,760 million from the prior outlook of
$5,610 to $5,760 million. The company has also upgraded its
adjusted earnings per share guidance to $3.96 to $4.01 from the
prior range of $3.95-$4.00. The current Zacks Consensus Estimates
for earnings per share and revenues for the year are pegged at
$3.98 and $5,701 million.
We are impressed with St. Jude Medical's second quarter results,
which topped estimates on both earnings and revenues fronts.
Moreover, the company's upgraded earnings and revenues guidance is
We are optimistic about the company's recent acquisition of
privately-held CardioMEMS, Inc. at the beginning of last month.
With the closure of the CardioMEMS acquisition, St. Jude Medical
expects accelerated growth in its cardiovascular segment.
Currently, St. Jude carries a Zacks Rank #2 (Buy).
Other stocks in the medical products industry that are also worth
OraSure Technologies, Inc.
Wright Medical Group Inc.
). All of them sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ST JUDE MEDICAL (STJ): Free Stock Analysis
HOSPIRA INC (HSP): Free Stock Analysis Report
WRIGHT MEDICAL (WMGI): Free Stock Analysis
ORASURE TECH (OSUR): Free Stock Analysis Report
To read this article on Zacks.com click here.